When examined by organ, although the frequency varies among reports, TTF‐1 is reported to be positive in 76.7% of adenocarcinomas, 87.6% of small cell carcinomas, 4% of squamous cell carcinomas, and 39.6% of large cell carcinomas among lung cancers. Here, TTF1 is linked to adenocarcinoma.